Nachrichten und Videos - AKARI THERAPEUTICS PLC ADS

...

...

...

...

...

...

Thinking about buying stock in Akari Therapeutics, Presbia Plc, Roku Inc., Snap Inc., or Pareteum Corp.? PR Newswire NEW YORK, March 14, 2019 NEW YORK , March 14, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKTX, LENS, ROKU, SNAP, and TEUM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AKTX:...

...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akari Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - AKTX PR Newswire NEW YORK, July 7, 2017 NEW YORK , July 7, 2017 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akari Therapeutics plc. ("Akari" or the "Company") (NASDAQ: AKTX) and certain of its officers. The class action, filed in United States District Court, Southern District of New...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Akari Therapeutics, Plc - AKTX PR Newswire NEW YORK, July 5, 2017 NEW YORK , July 5, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Akari Therapeutics, Plc (NASDAQ: AKTX) from March 30, 2017 through May 11, 2017 , both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages...

AKARI THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akari Therapeutics, Plc - (AKTX) PR Newswire NEW ORLEANS, June 2, 2017 NEW ORLEANS , June 2, 2017 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana , Charles C. Foti, Jr. , remind investors that they have until July 11, 2017 to file...

URGENT: Monteverde & Associates PC Invites Akari Therapeutics, Plc. Shareholders with Significant Losses To Contact The Firm Immediately - AKTX PR Newswire NEW YORK, June 1, 2017 NEW YORK , June 1, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York City announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New...

Investor Alert: Kaplan Fox Announces Investigation Of Akari Therapeutics, PLC PR Newswire NEW YORK, May 23, 2017 NEW YORK , May 23, 2017 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Akari Therapeutics, PLC ("Akari" or the "Company") (NASDAQ: AKTX). Class Action litigation has been filed in the United States District Court for the Southern District of New York against Akari and certain executives of the Company on behalf of...

IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm PR Newswire LOS ANGELES, May 22, 2017 LOS ANGELES , May 22, 2017 /PRNewswire/ -- Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc ("Akari" or the "Company") (Nasdaq: AKTX) concerning possible violations of federal securities laws between March 30, 2017 and...

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Akari Therapeutics, Plc To Contact The Firm PR Newswire NEW YORK, May 22, 2017 NEW YORK , May 22, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ: AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has...

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm PR Newswire LOS ANGELES, May 19, 2017 LOS ANGELES , May 19, 2017 /PRNewswire/ -- Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc ("Akari" or the "Company") (Nasdaq: AKTX) concerning possible violations of federal securities laws between March 30, 2017...

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm PR Newswire IRVINE, Calif., May 18, 2017 IRVINE, Calif. , May 18, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Akari Therapeutics, Plc ("Akari" or the "Company") (Nasdaq: AKTX). Investors who purchased or otherwise acquired shares between March 30, 2017 and...

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline: July 11, 2017 PR Newswire NEW YORK, May 18, 2017 NEW YORK , May 18, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akari Therapeutics Plc ("Akari" or the "Company") (NASDAQ: AKTX) and certain of its officers, on behalf of shareholders who...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akari Therapeutics Plc (AKTX) PR Newswire NEW YORK, May 12, 2017 NEW YORK , May 12, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akari Therapeutics Plc ("Akari" or the "Company") (NASDAQ: AKTX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site:...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akari Therapeutics plc - AKTX PR Newswire NEW YORK, May 12, 2017 NEW YORK , May 12, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Akari Therapeutics plc ("Akari" or the "Company") (NASDAQ: AKTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation concerns whether Akari and certain of its...